https://trial.medpath.com/news/apple-launches-research-app-with-three-major-health-studies-focusing-on-women-s-health-heart-disease-and-hearing 2019-11-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-launches-research-app-with-three-major-health-studies-focusing-on-women-s-health-heart-disease-and-hearing 2019-11-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tufts-researchers-develop-light-activated-insulin-production-system-for-diabetes-treatment 2019-11-08T20:05:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tufts-researchers-develop-light-activated-insulin-production-system-for-diabetes-treatment 2019-11-08T20:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/european-regulators-approve-lenacapavir-first-twice-yearly-hiv-prevention-injection 2019-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-regulators-approve-lenacapavir-first-twice-yearly-hiv-prevention-injection 2019-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-grants-conditional-approval-to-seaweed-derived-alzheimer-s-drug-oligomannate 2019-11-04T19:33:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-grants-conditional-approval-to-seaweed-derived-alzheimer-s-drug-oligomannate 2019-11-04T19:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/cyclin-dependent-kinase-4-6-inhibitor-in-combination-with-endocrine 2019-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyclin-dependent-kinase-4-6-inhibitor-in-combination-with-endocrine 2019-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-astellas-xospata-for-flt3-positive-aml-showing-survival-benefit-over-chemotherapy 2019-10-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-approves-astellas-xospata-for-flt3-positive-aml-showing-survival-benefit-over-chemotherapy 2019-10-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-enrolls-first-patient-in-phase-1-clinical-trial-of-rp2-for-advanced-cancer 2019-10-24T12:00:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-enrolls-first-patient-in-phase-1-clinical-trial-of-rp2-for-advanced-cancer 2019-10-24T12:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/nih-launches-influenza-human-challenge-study-to-advance-vaccine-development 2019-10-23T15:21:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-launches-influenza-human-challenge-study-to-advance-vaccine-development 2019-10-23T15:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/the-treatt-trial-evaluating-tranexamic-acid-in-haematological-malignancies 2019-10-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-treatt-trial-evaluating-tranexamic-acid-in-haematological-malignancies 2019-10-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/final-analysis-from-resonate-up-to-six-years-of-follow-up-on-ibrutinib-vs-ofatumumab-in-cll 2019-10-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-analysis-from-resonate-up-to-six-years-of-follow-up-on-ibrutinib-vs-ofatumumab-in-cll 2019-10-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/no-clinically-relevant-differences-in-qol-and-neurocognitive-function-with-lomustine-temozolomide-for-glioblastoma 2019-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-clinically-relevant-differences-in-qol-and-neurocognitive-function-with-lomustine-temozolomide-for-glioblastoma 2019-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/minimal-residual-disease-status-as-a-surrogate-endpoint 2019-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minimal-residual-disease-status-as-a-surrogate-endpoint 2019-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/focused-ultrasound-successfully-opens-blood-brain-barrier-in-als-patients-groundbreaking-trial-results 2019-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/focused-ultrasound-successfully-opens-blood-brain-barrier-in-als-patients-groundbreaking-trial-results 2019-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/small-clinical-trial-shows-drug-cocktail-reverses-biological-age-by-2-5-years 2019-09-10T19:56:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/small-clinical-trial-shows-drug-cocktail-reverses-biological-age-by-2-5-years 2019-09-10T19:56:06+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-retention-crisis-30-dropout-rate-costs-industry-billions-and-delays-drug-development 2019-09-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-retention-crisis-30-dropout-rate-costs-industry-billions-and-delays-drug-development 2019-09-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/minimal-residual-disease-status-as-a-surrogate-endpoint-for-pubmed 2019-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minimal-residual-disease-status-as-a-surrogate-endpoint-for-pubmed 2019-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doxycycline-prophylaxis-for-bacterial-sexually-transmitted 2019-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doxycycline-prophylaxis-for-bacterial-sexually-transmitted 2019-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/four-drug-polypill-reduces-heart-attack-and-stroke-risk-by-34-in-landmark-trial 2019-08-23T00:17:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/four-drug-polypill-reduces-heart-attack-and-stroke-risk-by-34-in-landmark-trial 2019-08-23T00:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/rna-targeted-drug-discovery-summit-to-explore-breakthrough-small-molecule-therapeutics 2019-08-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rna-targeted-drug-discovery-summit-to-explore-breakthrough-small-molecule-therapeutics 2019-08-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eptinezumab-shows-promise-in-preventing-chronic-migraine 2019-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eptinezumab-shows-promise-in-preventing-chronic-migraine 2019-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-tecentriq-combination-shows-promise-in-advanced-bladder-cancer-phase-iii-trial 2019-08-05T09:17:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-tecentriq-combination-shows-promise-in-advanced-bladder-cancer-phase-iii-trial 2019-08-05T09:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pexidartinib-as-first-treatment-for-tenosynovial-giant-cell-tumour 2019-08-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pexidartinib-as-first-treatment-for-tenosynovial-giant-cell-tumour 2019-08-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-of-the-glycoprotein-non-metastatic-b-targeted 2019-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-trial-of-the-glycoprotein-non-metastatic-b-targeted 2019-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-expands-drug-discovery-portfolio-with-three-strategic-platform-partnerships 2019-07-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genentech-expands-drug-discovery-portfolio-with-three-strategic-platform-partnerships 2019-07-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-merck-s-recarbrio-for-complex-infections-with-antimicrobial-stewardship-focus 2019-07-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-merck-s-recarbrio-for-complex-infections-with-antimicrobial-stewardship-focus 2019-07-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-ceo-outlines-vision-for-clinical-trial-evolution-balancing-innovation-with-regulatory-compliance 2019-07-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-ceo-outlines-vision-for-clinical-trial-evolution-balancing-innovation-with-regulatory-compliance 2019-07-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alder-biopharmaceuticals-presents-new-data-on-eptinezumab-s-clinical-profile-for-migraine-prevention 2019-07-12T02:40:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alder-biopharmaceuticals-presents-new-data-on-eptinezumab-s-clinical-profile-for-migraine-prevention 2019-07-12T02:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-radiographic-evaluation-of-biodentine-in-revascularization-of-non-vital-immature-teeth 2019-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-and-radiographic-evaluation-of-biodentine-in-revascularization-of-non-vital-immature-teeth 2019-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-appeals-nice-rejection-of-tagrisso-for-first-line-nsclc-treatment 2019-07-08T11:39:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-appeals-nice-rejection-of-tagrisso-for-first-line-nsclc-treatment 2019-07-08T11:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-of-monitoring-compliance-with-intermittent-occlusion-therapy-glasses-for-amblyopia-treatment 2019-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feasibility-of-monitoring-compliance-with-intermittent-occlusion-therapy-glasses-for-amblyopia-treatment 2019-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-transforms-drug-development-fda-embraces-new-paradigm-in-clinical-research 2019-06-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-transforms-drug-development-fda-embraces-new-paradigm-in-clinical-research 2019-06-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/denali-s-hunter-syndrome-candidate-receives-fda-orphan-drug-and-rare-pediatric-disease-designations 2019-06-12T14:30:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/denali-s-hunter-syndrome-candidate-receives-fda-orphan-drug-and-rare-pediatric-disease-designations 2019-06-12T14:30:02+00:00 weekly 0.7 https://trial.medpath.com/news/smi-s-9th-annual-orphan-drugs-conference-to-address-key-challenges-in-rare-disease-treatment-access 2019-06-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/smi-s-9th-annual-orphan-drugs-conference-to-address-key-challenges-in-rare-disease-treatment-access 2019-06-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-receives-fda-approval-for-alfapump-device-trial 2019-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-receives-fda-approval-for-alfapump-device-trial 2019-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-drug-shows-potential-to-cure-advanced-lung-cancer 2019-05-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-drug-shows-potential-to-cure-advanced-lung-cancer 2019-05-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-receives-patent-for-novel-nlrp3-inflammasome-inhibitors-with-potential-for-multiple-inflammatory-diseases 2019-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-receives-patent-for-novel-nlrp3-inflammasome-inhibitors-with-potential-for-multiple-inflammatory-diseases 2019-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leading-pharma-companies-unite-at-social-media-conference-to-share-digital-innovation-strategies 2019-05-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leading-pharma-companies-unite-at-social-media-conference-to-share-digital-innovation-strategies 2019-05-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-real-world-evidence-framework-to-accelerate-drug-approvals-and-support-regulatory-decisions 2019-05-10T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-real-world-evidence-framework-to-accelerate-drug-approvals-and-support-regulatory-decisions 2019-05-10T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-updated-clinical-data-from-phase-iib-study-of-amt-061-in-hemophilia-b-patients 2019-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-announces-updated-clinical-data-from-phase-iib-study-of-amt-061-in-hemophilia-b-patients 2019-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-pharma-announces-first-participant-enrolled-in-zupreme-1-phase-2b-trial 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zealand-pharma-announces-first-participant-enrolled-in-zupreme-1-phase-2b-trial 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-tagrisso-combination-therapy-extends-survival-to-nearly-four-years-in-advanced-lung-cancer 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-tagrisso-combination-therapy-extends-survival-to-nearly-four-years-in-advanced-lung-cancer 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-s-tobevibart-and-elebsiran-receive-fda-and-ema-designations-for-chronic-hepatitis-delta-treatment 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-s-tobevibart-and-elebsiran-receive-fda-and-ema-designations-for-chronic-hepatitis-delta-treatment 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-telix-s-kidney-cancer-imaging-agent-tlx250-cdx 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-telix-s-kidney-cancer-imaging-agent-tlx250-cdx 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rapport-therapeutics-prepares-to-report-phase-iia-epilepsy-trial-results-for-rap-219 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapport-therapeutics-prepares-to-report-phase-iia-epilepsy-trial-results-for-rap-219 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-for-gsk-s-osteosarcoma-treatment 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-for-gsk-s-osteosarcoma-treatment 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rmat-designation-to-mesoblast-s-revascor-for-pediatric-hypoplastic-left-heart-syndrome 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-mesoblast-s-revascor-for-pediatric-hypoplastic-left-heart-syndrome 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nih-study-finds-siga-s-tecovirimat-did-not-improve-mpox-resolution-or-pain 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-study-finds-siga-s-tecovirimat-did-not-improve-mpox-resolution-or-pain 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-s-cancer-drug-trastuzumab-pamirtecan-meets-primary-endpoint-in-phase-3-breast-cancer-trial 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biontech-s-cancer-drug-trastuzumab-pamirtecan-meets-primary-endpoint-in-phase-3-breast-cancer-trial 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-advances-als-treatment-with-primec-through-strategic-partnership 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-advances-als-treatment-with-primec-through-strategic-partnership 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/precigen-receives-fda-approval-for-papzimeos-first-treatment-for-recurrent-respiratory-papillomatosis 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precigen-receives-fda-approval-for-papzimeos-first-treatment-for-recurrent-respiratory-papillomatosis 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytomed-soars-on-research-deal-with-sunact-cancer-institute-for-solid-tumor-treatment-trial-in-india 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytomed-soars-on-research-deal-with-sunact-cancer-institute-for-solid-tumor-treatment-trial-in-india 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/remegen-s-telitacicept-achieves-55-proteinuria-reduction-in-phase-3-iga-nephropathy-trial 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remegen-s-telitacicept-achieves-55-proteinuria-reduction-in-phase-3-iga-nephropathy-trial 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-ionis-pharmaceuticals-nda-for-donidalorsen-as-prophylactic-treatment-for-hae 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-ionis-pharmaceuticals-nda-for-donidalorsen-as-prophylactic-treatment-for-hae 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-s-phase-iib-study-of-prasinezumab-in-early-stage-parkinson-s-disease-misses-primary-goal 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genentech-s-phase-iib-study-of-prasinezumab-in-early-stage-parkinson-s-disease-misses-primary-goal 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-and-ce-ivdr-approvals-for-expanded-her2-diagnostic-applications-in-cancer-treatment 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-receives-fda-and-ce-ivdr-approvals-for-expanded-her2-diagnostic-applications-in-cancer-treatment 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-henlius-organon-denosumab-biosimilars-bildyos-and-bilprevda-for-bone-health-conditions 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-henlius-organon-denosumab-biosimilars-bildyos-and-bilprevda-for-bone-health-conditions 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hybrytetm-a-promising-photodynamic-therapy-for-cutaneous-t-cell-lymphoma-ctcl 2019-05-01T15:53:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hybrytetm-a-promising-photodynamic-therapy-for-cutaneous-t-cell-lymphoma-ctcl 2019-05-01T15:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-breakthrough-effectively-cures-bubble-boy-disease-in-infants 2019-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-breakthrough-effectively-cures-bubble-boy-disease-in-infants 2019-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/qgel-s-synthetic-matrix-breakthrough-aims-to-revolutionize-organoid-based-precision-medicine 2019-04-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qgel-s-synthetic-matrix-breakthrough-aims-to-revolutionize-organoid-based-precision-medicine 2019-04-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/overview-of-advanced-therapy-medicinal-products-atmps-in-the-european-union 2019-04-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/overview-of-advanced-therapy-medicinal-products-atmps-in-the-european-union 2019-04-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/patient-centric-websites-and-plain-language-key-to-boosting-clinical-trial-recruitment 2019-04-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-centric-websites-and-plain-language-key-to-boosting-clinical-trial-recruitment 2019-04-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-and-daiichi-sankyo-partner-in-6-9b-deal-for-novel-her2-targeting-cancer-drug 2019-03-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-and-daiichi-sankyo-partner-in-6-9b-deal-for-novel-her2-targeting-cancer-drug 2019-03-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-pilot-trial-on-first-pass-intubation-success-rates 2019-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feasibility-pilot-trial-on-first-pass-intubation-success-rates 2019-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fgfr1-overexpression-identified-as-a-key-resistance-mechanism-to-cdk4-6-inhibitors-in-er-breast-cancer 2019-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fgfr1-overexpression-identified-as-a-key-resistance-mechanism-to-cdk4-6-inhibitors-in-er-breast-cancer 2019-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-kgaa-partners-with-iktos-to-accelerate-drug-discovery-through-ai-powered-molecular-design 2019-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-kgaa-partners-with-iktos-to-accelerate-drug-discovery-through-ai-powered-molecular-design 2019-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brainstorm-announces-first-patient-in-phase-2-clinical-trial-for-progressive-ms 2019-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brainstorm-announces-first-patient-in-phase-2-clinical-trial-for-progressive-ms 2019-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovations-and-trials-in-medical-technology 2019-03-12T14:07:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovations-and-trials-in-medical-technology 2019-03-12T14:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/expanding-cancer-clinical-trial-eligibility-to-include-more-patients 2019-03-07T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expanding-cancer-clinical-trial-eligibility-to-include-more-patients 2019-03-07T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-resmetirom-rezdiffra-for-treating-mash-and-associated-fibrosis 2019-02-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-resmetirom-rezdiffra-for-treating-mash-and-associated-fibrosis 2019-02-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alteogen-secures-process-patent-for-aflibercept-biosimilar-claims-competitive-advantage 2019-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alteogen-secures-process-patent-for-aflibercept-biosimilar-claims-competitive-advantage 2019-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ohsu-researchers-develop-promising-long-lasting-malaria-vaccine-using-novel-viral-platform 2019-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ohsu-researchers-develop-promising-long-lasting-malaria-vaccine-using-novel-viral-platform 2019-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ontruzant-samsung-bioepis-and-merck-s-biosimilar-to-herceptin-for-cancer-treatment 2019-01-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ontruzant-samsung-bioepis-and-merck-s-biosimilar-to-herceptin-for-cancer-treatment 2019-01-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-liquid-biopsy-system-shows-promise-in-preventing-cancer-metastasis 2019-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-liquid-biopsy-system-shows-promise-in-preventing-cancer-metastasis 2019-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-explores-treatment-for-hot-flashes-in-women-with-hr-positive-breast-cancer 2019-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-explores-treatment-for-hot-flashes-in-women-with-hr-positive-breast-cancer 2019-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mallinckrodt-s-specgx-llc-receives-fda-complete-response-letter-for-abuse-deterrent-immediate-release-reformulation-of-roxicodone-r-oxycodone-hydrochloride 2018-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mallinckrodt-s-specgx-llc-receives-fda-complete-response-letter-for-abuse-deterrent-immediate-release-reformulation-of-roxicodone-r-oxycodone-hydrochloride 2018-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-fox-chase-trial-tests-risk-adapted-approach 2018-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-fox-chase-trial-tests-risk-adapted-approach 2018-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-unveils-new-five-year-drug-pricing-agreement-to-accelerate-nhs-medicine-access 2018-11-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-unveils-new-five-year-drug-pricing-agreement-to-accelerate-nhs-medicine-access 2018-11-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-treatment-for-primary-hemophagocytic-lymphohistiocytosis-marking-24-year-breakthrough 2018-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-treatment-for-primary-hemophagocytic-lymphohistiocytosis-marking-24-year-breakthrough 2018-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-bortezomib-rituximab-cyclophosphamide 2018-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-bortezomib-rituximab-cyclophosphamide 2018-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-direct-to-consumer-pharmacogenetic-test-from-23andme 2018-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-direct-to-consumer-pharmacogenetic-test-from-23andme 2018-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-launches-biome-innovation-lab-network-to-accelerate-digital-health-solutions 2018-10-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-launches-biome-innovation-lab-network-to-accelerate-digital-health-solutions 2018-10-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-strengthens-digital-strategy-with-new-chief-digital-officer-appointment 2018-10-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-strengthens-digital-strategy-with-new-chief-digital-officer-appointment 2018-10-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-launches-cybersecurity-playbook-to-protect-medical-devices-from-digital-threats 2018-10-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-launches-cybersecurity-playbook-to-protect-medical-devices-from-digital-threats 2018-10-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-continuous-manufacturing-journey-pioneering-success-with-hiv-drug-prezista 2018-09-24T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-continuous-manufacturing-journey-pioneering-success-with-hiv-drug-prezista 2018-09-24T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/survey-reveals-gap-between-patient-centric-aspirations-and-implementation-in-pharma-industry 2018-09-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survey-reveals-gap-between-patient-centric-aspirations-and-implementation-in-pharma-industry 2018-09-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/life-molecular-imaging-secures-fda-fast-track-designation-for-18f-florbetaben-in-cardiac-amyloidosis-diagnosis 2018-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/life-molecular-imaging-secures-fda-fast-track-designation-for-18f-florbetaben-in-cardiac-amyloidosis-diagnosis 2018-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-sanofi-s-cablivi-as-first-targeted-therapy-for-rare-blood-clotting-disorder-attp 2018-09-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-approves-sanofi-s-cablivi-as-first-targeted-therapy-for-rare-blood-clotting-disorder-attp 2018-09-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-participants-randomized-in-askbio-phase-ii-gene-therapy-trial-for-parkinsons-disease 2018-08-27T14:25:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-participants-randomized-in-askbio-phase-ii-gene-therapy-trial-for-parkinsons-disease 2018-08-27T14:25:15+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolutionizes-drug-discovery-major-tech-companies-and-startups-lead-innovation-wave 2018-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-revolutionizes-drug-discovery-major-tech-companies-and-startups-lead-innovation-wave 2018-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-novel-triplet-combination-for-braf-mutant-metastatic-colorectal-cancer 2018-08-07T19:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-novel-triplet-combination-for-braf-mutant-metastatic-colorectal-cancer 2018-08-07T19:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-partners-with-uk-consortium-to-develop-novel-gene-therapy-for-cystic-fibrosis 2018-08-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-partners-with-uk-consortium-to-develop-novel-gene-therapy-for-cystic-fibrosis 2018-08-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytic-virus-therapy-emerges-as-promising-cancer-treatment-breakthrough 2018-08-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncolytic-virus-therapy-emerges-as-promising-cancer-treatment-breakthrough 2018-08-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-precision-medicine-with-synthetic-nearest-neighbors-in-clinical-trials 2018-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-precision-medicine-with-synthetic-nearest-neighbors-in-clinical-trials 2018-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/low-dose-nivolumab-shows-promise-as-cost-effective-alternative-for-nsclc-treatment 2018-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-dose-nivolumab-shows-promise-as-cost-effective-alternative-for-nsclc-treatment 2018-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-backs-novel-therapies-onpattro-for-hattr-and-symkevi-for-cystic-fibrosis 2018-07-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-backs-novel-therapies-onpattro-for-hattr-and-symkevi-for-cystic-fibrosis 2018-07-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alder-biopharmaceuticals-to-showcase-eptinezumab-s-efficacy-in-migraine-prevention-at-ahs-meeting 2018-07-05T08:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alder-biopharmaceuticals-to-showcase-eptinezumab-s-efficacy-in-migraine-prevention-at-ahs-meeting 2018-07-05T08:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-establishes-eur66-million-global-r-d-hub-in-chengdu-expanding-china-research-footprint 2018-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-establishes-eur66-million-global-r-d-hub-in-chengdu-expanding-china-research-footprint 2018-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genetic-variants-and-their-impact-on-clinical-responses-to-treatments 2018-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genetic-variants-and-their-impact-on-clinical-responses-to-treatments 2018-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vedolizumab-a-new-therapeutic-option-for-inflammatory-bowel-disease 2018-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vedolizumab-a-new-therapeutic-option-for-inflammatory-bowel-disease 2018-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-amgen-and-sanofi-partner-to-leverage-blockchain-technology-in-clinical-trials 2018-06-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-amgen-and-sanofi-partner-to-leverage-blockchain-technology-in-clinical-trials 2018-06-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rising-demand-for-comparator-clinical-trials-reshapes-drug-development-landscape 2018-06-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-demand-for-comparator-clinical-trials-reshapes-drug-development-landscape 2018-06-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-immunotherapy-success-in-prostate-cancer-shows-promise-for-dna-repair-deficient-tumors 2018-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-immunotherapy-success-in-prostate-cancer-shows-promise-for-dna-repair-deficient-tumors 2018-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/landmark-tailorx-trial-shows-70-of-early-stage-breast-cancer-patients-can-safely-skip-chemotherapy 2018-06-03T11:50:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/landmark-tailorx-trial-shows-70-of-early-stage-breast-cancer-patients-can-safely-skip-chemotherapy 2018-06-03T11:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-partners-with-cloud-pharmaceuticals-to-accelerate-drug-discovery-through-ai-technology 2018-05-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-partners-with-cloud-pharmaceuticals-to-accelerate-drug-discovery-through-ai-technology 2018-05-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-editing-restores-dystrophin-expression-in-a-canine-model-of 2018-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-editing-restores-dystrophin-expression-in-a-canine-model-of 2018-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neuclone-gibt-praklinische-ergebnisse-von-biosimilar-kandidaten-fur-stelara-r-ustekinumab-bekannt 2018-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuclone-gibt-praklinische-ergebnisse-von-biosimilar-kandidaten-fur-stelara-r-ustekinumab-bekannt 2018-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-multicenter-prospective-single-arm-open-label 2018-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multicenter-prospective-single-arm-open-label 2018-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-sandoz-partners-with-pear-therapeutics-to-combat-substance-use-disorders-with-digital-solutions 2018-04-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-sandoz-partners-with-pear-therapeutics-to-combat-substance-use-disorders-with-digital-solutions 2018-04-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alder-biopharmaceuticals-to-present-new-phase-3-migraine-prevention-data-for-eptinezumab 2018-04-18T14:31:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alder-biopharmaceuticals-to-present-new-phase-3-migraine-prevention-data-for-eptinezumab 2018-04-18T14:31:23+00:00 weekly 0.7 https://trial.medpath.com/news/blockchain-technology-poised-to-transform-pharmaceutical-supply-chain-security-and-traceability 2018-04-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blockchain-technology-poised-to-transform-pharmaceutical-supply-chain-security-and-traceability 2018-04-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/survey-reveals-critical-gap-in-patient-engagement-across-clinical-trial-industry 2018-04-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survey-reveals-critical-gap-in-patient-engagement-across-clinical-trial-industry 2018-04-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-teva-and-celltrion-s-biosimilars-for-rituxan-and-herceptin-due-to-manufacturing-issues 2018-04-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejects-teva-and-celltrion-s-biosimilars-for-rituxan-and-herceptin-due-to-manufacturing-issues 2018-04-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-ipilimumab-may-be-a-new-first-line 2018-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-plus-ipilimumab-may-be-a-new-first-line 2018-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/final-5-year-results-of-the-phase-2-pace-trial-for-cml-and-ph-all-patients 2018-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-5-year-results-of-the-phase-2-pace-trial-for-cml-and-ph-all-patients 2018-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nice-rejects-cenegermin-for-rare-eye-disease-citing-cost-concerns 2018-03-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nice-rejects-cenegermin-for-rare-eye-disease-citing-cost-concerns 2018-03-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-watch-phase-iii-starts-with-oxabact-imeglimin-and 2018-03-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-watch-phase-iii-starts-with-oxabact-imeglimin-and 2018-03-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-status-to-3i-diagnostics-rapid-blood-infection-test 2018-03-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-status-to-3i-diagnostics-rapid-blood-infection-test 2018-03-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/overly-restrictive-clinical-trial-exclusion-criteria-may-block-patients 2018-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/overly-restrictive-clinical-trial-exclusion-criteria-may-block-patients 2018-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytic-viruses-gain-momentum-in-cancer-treatment-following-merck-s-394m-viralytics-acquisition 2018-02-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncolytic-viruses-gain-momentum-in-cancer-treatment-following-merck-s-394m-viralytics-acquisition 2018-02-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-elagolix-demonstrates-significant-efficacy-in-two-phase-3-trials-for-uterine-fibroids 2018-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-elagolix-demonstrates-significant-efficacy-in-two-phase-3-trials-for-uterine-fibroids 2018-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-blockchain-and-big-data-new-technologies-promise-to-slash-pharmaceutical-r-d-costs 2018-02-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-blockchain-and-big-data-new-technologies-promise-to-slash-pharmaceutical-r-d-costs 2018-02-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stanford-researchers-develop-injectable-cancer-vaccine-that-eliminates-tumors-in-mice 2018-01-31T19:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stanford-researchers-develop-injectable-cancer-vaccine-that-eliminates-tumors-in-mice 2018-01-31T19:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/former-eli-lilly-executive-alex-azar-sworn-in-as-us-health-secretary-pledges-to-combat-high-drug-prices 2018-01-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/former-eli-lilly-executive-alex-azar-sworn-in-as-us-health-secretary-pledges-to-combat-high-drug-prices 2018-01-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-outsourcing-set-to-reach-72-by-2020-as-industry-embraces-cro-partnerships 2018-01-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-outsourcing-set-to-reach-72-by-2020-as-industry-embraces-cro-partnerships 2018-01-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-ocrevus-to-match-novartis-s-gilenya-pricing-in-uk-ms-market 2018-01-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-ocrevus-to-match-novartis-s-gilenya-pricing-in-uk-ms-market 2018-01-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/janssen-to-address-key-challenges-in-drug-device-combination-product-development-at-pre-filled-syringes-conference 2018-01-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/janssen-to-address-key-challenges-in-drug-device-combination-product-development-at-pre-filled-syringes-conference 2018-01-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-on-telisotuzumab-vedotin-shows-promise-for-c-met-positive-nsclc-patients 2018-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-on-telisotuzumab-vedotin-shows-promise-for-c-met-positive-nsclc-patients 2018-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-lenvima-keytruda-combination-for-advanced-renal-cell-carcinoma 2018-01-09T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-lenvima-keytruda-combination-for-advanced-renal-cell-carcinoma 2018-01-09T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/landiolol-pharmacology-and-its-use-for-rate-control-in-atrial 2018-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/landiolol-pharmacology-and-its-use-for-rate-control-in-atrial 2018-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/futura-medical-s-med2005-shows-promise-as-rapid-acting-topical-treatment-for-erectile-dysfunction 2018-01-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/futura-medical-s-med2005-shows-promise-as-rapid-acting-topical-treatment-for-erectile-dysfunction 2018-01-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-agrees-to-acquire-siteone-therapeutics-for-up-to-1-billion-in-non-opioid-pain-therapy-deal 2018-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-agrees-to-acquire-siteone-therapeutics-for-up-to-1-billion-in-non-opioid-pain-therapy-deal 2018-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-internal-cooling-offers-better-survival-outcomes-for-post-cardiac-arrest-patients 2018-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-internal-cooling-offers-better-survival-outcomes-for-post-cardiac-arrest-patients 2018-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/articles-archives-drug-hunter 2018-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/articles-archives-drug-hunter 2018-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-survey-reveals-complex-landscape-of-pharmaceutical-market-access-challenges 2017-12-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-survey-reveals-complex-landscape-of-pharmaceutical-market-access-challenges 2017-12-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-database-delays-significantly-impact-trial-timelines-tufts-study-reveals 2017-12-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-database-delays-significantly-impact-trial-timelines-tufts-study-reveals 2017-12-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/protection-of-the-human-gut-microbiome-from-antibiotics 2017-11-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protection-of-the-human-gut-microbiome-from-antibiotics 2017-11-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leading-pharma-companies-and-regulators-to-convene-at-10th-annual-adaptive-clinical-trials-conference 2017-11-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leading-pharma-companies-and-regulators-to-convene-at-10th-annual-adaptive-clinical-trials-conference 2017-11-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-investigational-bcma-antibody-drug-conjugate 2017-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-s-investigational-bcma-antibody-drug-conjugate 2017-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-pharmaceutical-r-d-evolution-regulatory-reforms-signal-new-era-for-drug-development 2017-10-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-s-pharmaceutical-r-d-evolution-regulatory-reforms-signal-new-era-for-drug-development 2017-10-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-oncology-biosimilars-set-to-generate-eur2-billion-in-healthcare-savings-by-2021 2017-10-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-oncology-biosimilars-set-to-generate-eur2-billion-in-healthcare-savings-by-2021 2017-10-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mylan-s-generic-versions-of-copaxone-for-multiple-sclerosis-treatment 2017-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-mylan-s-generic-versions-of-copaxone-for-multiple-sclerosis-treatment 2017-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-traumatic-brain-injury-treatment-through-the-ted-initiative 2017-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-traumatic-brain-injury-treatment-through-the-ted-initiative 2017-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-launches-with-103m-to-advance-pfizer-s-rare-disease-portfolio 2017-09-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springworks-therapeutics-launches-with-103m-to-advance-pfizer-s-rare-disease-portfolio 2017-09-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ibrutinib-shows-promise-in-treating-chronic-graft-versus-host-disease 2017-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ibrutinib-shows-promise-in-treating-chronic-graft-versus-host-disease 2017-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-s-kymriah-breakthrough-car-t-therapy-priced-at-475000-sparks-value-debate 2017-09-06T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-s-kymriah-breakthrough-car-t-therapy-priced-at-475000-sparks-value-debate 2017-09-06T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/catalyst-biosciences-announces-positive-factor-ix-clinical-data 2017-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/catalyst-biosciences-announces-positive-factor-ix-clinical-data 2017-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-shows-high-efficacy-of-boven-regimen-in-treating-chronic-lymphocytic-leukaemia 2017-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-trial-shows-high-efficacy-of-boven-regimen-in-treating-chronic-lymphocytic-leukaemia 2017-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-a-triple-combination-of-atezolizumab 2017-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-a-triple-combination-of-atezolizumab 2017-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-approaches-to-securing-market-access-for-orphan-drugs-beyond-hta-approval 2017-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-approaches-to-securing-market-access-for-orphan-drugs-beyond-hta-approval 2017-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medical-affairs-evolution-eisai-s-kirk-shepard-leads-transformation-towards-patient-centric-pharma 2017-08-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medical-affairs-evolution-eisai-s-kirk-shepard-leads-transformation-towards-patient-centric-pharma 2017-08-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alicaforsen-shows-promise-in-treating-inflammatory-bowel-disease 2017-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alicaforsen-shows-promise-in-treating-inflammatory-bowel-disease 2017-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-drugs-unexpectedly-restore-hair-color-in-lung-cancer-patients 2017-07-27T16:28:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-drugs-unexpectedly-restore-hair-color-in-lung-cancer-patients 2017-07-27T16:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-full-approval-to-blinatumomab-for-b-cell-precursor-all 2017-07-12T18:08:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-full-approval-to-blinatumomab-for-b-cell-precursor-all 2017-07-12T18:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/patient-centric-approaches-and-technology-reshape-clinical-trial-landscape-industry-experts-report 2017-07-12T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-centric-approaches-and-technology-reshape-clinical-trial-landscape-industry-experts-report 2017-07-12T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/manali-kamdar-s-contributions-to-lymphoma-treatment-research 2017-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/manali-kamdar-s-contributions-to-lymphoma-treatment-research 2017-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/soleno-therapeutics-announces-successful-completion-of-fda-meeting-for-dccr-in-prader-willi-syndrome 2017-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soleno-therapeutics-announces-successful-completion-of-fda-meeting-for-dccr-in-prader-willi-syndrome 2017-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-partners-with-exscientia-in-ps33m-ai-driven-drug-discovery-alliance 2017-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-partners-with-exscientia-in-ps33m-ai-driven-drug-discovery-alliance 2017-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alder-biopharmaceuticals-announces-positive-eptinezumab-phase-3-results-for-migraine-prevention 2017-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alder-biopharmaceuticals-announces-positive-eptinezumab-phase-3-results-for-migraine-prevention 2017-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-for-glioblastoma-shows-promise-in-early-study 2017-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-for-glioblastoma-shows-promise-in-early-study 2017-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-data-sharing-initiatives-drive-innovation-and-efficiency-in-drug-development 2017-06-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-data-sharing-initiatives-drive-innovation-and-efficiency-in-drug-development 2017-06-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/actinium-pharmaceuticals-granted-orphan-designation-from 2017-05-24T09:23:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actinium-pharmaceuticals-granted-orphan-designation-from 2017-05-24T09:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/dynamic-consent-platforms-revolutionizing-clinical-trial-participation-and-data-management 2017-05-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dynamic-consent-platforms-revolutionizing-clinical-trial-participation-and-data-management 2017-05-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/celltrion-pursues-novel-multi-brand-strategy-for-rituximab-biosimilar-in-eu-market 2017-05-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celltrion-pursues-novel-multi-brand-strategy-for-rituximab-biosimilar-in-eu-market 2017-05-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-shows-superior-weight-loss-efficacy-over-semaglutide-in-real-world-study 2017-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-shows-superior-weight-loss-efficacy-over-semaglutide-in-real-world-study 2017-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-fourth-alk-inhibitor-for-lung-cancer 2017-05-05T18:31:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-fourth-alk-inhibitor-for-lung-cancer 2017-05-05T18:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/review-of-the-drug-trials-snapshots-program-of-the-us 2017-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/review-of-the-drug-trials-snapshots-program-of-the-us 2017-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-for-glioblastoma-shows-promise-in-early-study 2017-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-for-glioblastoma-shows-promise-in-early-study 2017-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/benevolentai-partners-with-mrc-technology-to-accelerate-ai-driven-drug-discovery 2017-04-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benevolentai-partners-with-mrc-technology-to-accelerate-ai-driven-drug-discovery 2017-04-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jim-mellon-backs-insilico-medicine-s-ai-driven-anti-aging-drug-discovery-platform 2017-04-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jim-mellon-backs-insilico-medicine-s-ai-driven-anti-aging-drug-discovery-platform 2017-04-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bavencio-merck-kgaa-and-pfizer-s-breakthrough-immunotherapy-for-rare-skin-cancer 2017-03-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bavencio-merck-kgaa-and-pfizer-s-breakthrough-immunotherapy-for-rare-skin-cancer 2017-03-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/als-clinical-trials-review-20-years-of-failure-are-we 2017-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/als-clinical-trials-review-20-years-of-failure-are-we 2017-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-marks-biosimilars-milestone-with-1b-sales-plans-five-major-launches-by-2020 2017-03-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sandoz-marks-biosimilars-milestone-with-1b-sales-plans-five-major-launches-by-2020 2017-03-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-leverages-ai-to-transform-drug-development-decision-making-process 2017-02-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-leverages-ai-to-transform-drug-development-decision-making-process 2017-02-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nice-rejects-alexion-s-kanuma-for-ultra-rare-lal-d-treatment-citing-high-costs 2017-02-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nice-rejects-alexion-s-kanuma-for-ultra-rare-lal-d-treatment-citing-high-costs 2017-02-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/image-analysis-group-and-alimentiv-form-strategic-partnership-to-advance-ai-driven-gastroenterology-clinical-trials 2017-02-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/image-analysis-group-and-alimentiv-form-strategic-partnership-to-advance-ai-driven-gastroenterology-clinical-trials 2017-02-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/minimal-residual-disease-predicts-superior-survival-in 2017-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minimal-residual-disease-predicts-superior-survival-in 2017-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mabvax-therapeutics-expands-phase-i-clinical-trial-for-pancreatic-cancer-treatment 2016-12-05T18:30:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mabvax-therapeutics-expands-phase-i-clinical-trial-for-pancreatic-cancer-treatment 2016-12-05T18:30:42+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-shows-promise-in-reducing-depression-and-anxiety-in-cancer-patients 2016-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilocybin-shows-promise-in-reducing-depression-and-anxiety-in-cancer-patients 2016-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nice-proposes-three-tier-cost-effectiveness-framework-for-drug-evaluation-in-uk 2016-11-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nice-proposes-three-tier-cost-effectiveness-framework-for-drug-evaluation-in-uk 2016-11-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rival-diabetes-combinations-xultophy-and-soliqua-for-type-2-diabetes-management 2016-11-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-rival-diabetes-combinations-xultophy-and-soliqua-for-type-2-diabetes-management 2016-11-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-bone-cancer-treatment-granted-fda-breakthrough 2016-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-bone-cancer-treatment-granted-fda-breakthrough 2016-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teva-and-ibm-watson-partner-to-accelerate-ai-driven-drug-repurposing-initiative 2016-10-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-and-ibm-watson-partner-to-accelerate-ai-driven-drug-repurposing-initiative 2016-10-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kymab-and-epimab-form-strategic-alliance-to-develop-novel-bispecific-antibodies-for-cancer-treatment 2016-10-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymab-and-epimab-form-strategic-alliance-to-develop-novel-bispecific-antibodies-for-cancer-treatment 2016-10-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-cancer-drug-nivolumab-hailed-as-game-changer 2016-10-09T06:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-cancer-drug-nivolumab-hailed-as-game-changer 2016-10-09T06:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/encouraging-results-for-ribociclib-in-advanced-breast-cancer 2016-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/encouraging-results-for-ribociclib-in-advanced-breast-cancer 2016-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-framework-for-early-asset-development-integrating-clinical-patient-and-commercial-value 2016-10-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-framework-for-early-asset-development-integrating-clinical-patient-and-commercial-value 2016-10-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/verily-partners-with-dutch-institutions-to-launch-large-scale-parkinson-s-disease-study 2016-10-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verily-partners-with-dutch-institutions-to-launch-large-scale-parkinson-s-disease-study 2016-10-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/inspiring-hope-ideathon-launches-global-initiative-to-boost-clinical-trial-participation 2016-09-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspiring-hope-ideathon-launches-global-initiative-to-boost-clinical-trial-participation 2016-09-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-immunotherapy-for-leukemia-shows-promise-in-small-clinical-trial 2016-09-21T18:00:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-immunotherapy-for-leukemia-shows-promise-in-small-clinical-trial 2016-09-21T18:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-sandoz-s-erelzi-as-first-enbrel-biosimilar-in-us 2016-08-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-sandoz-s-erelzi-as-first-enbrel-biosimilar-in-us 2016-08-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-guide-clinical-trial-regulatory-pathways-across-10-asia-pacific-nations 2016-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-guide-clinical-trial-regulatory-pathways-across-10-asia-pacific-nations 2016-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-protocol-for-a-randomized-controlled-non-inferiority-trial-on-blended-depression-treatment-in-europe 2016-08-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-protocol-for-a-randomized-controlled-non-inferiority-trial-on-blended-depression-treatment-in-europe 2016-08-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/precision-oncology-medicine-the-clinical-relevance-of-patient-specific-biomarkers-used-to-optimize-cancer-treatment 2016-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-oncology-medicine-the-clinical-relevance-of-patient-specific-biomarkers-used-to-optimize-cancer-treatment 2016-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shionogi-announces-acceptance-of-new-drug-application-in-the 2016-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shionogi-announces-acceptance-of-new-drug-application-in-the 2016-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/an-exploration-of-the-impact-of-initial-timing-of-physical-therapy-on 2016-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-exploration-of-the-impact-of-initial-timing-of-physical-therapy-on 2016-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/risk-based-monitoring-revolutionizes-clinical-trial-quality-management 2016-05-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-based-monitoring-revolutionizes-clinical-trial-quality-management 2016-05-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-reveals-key-strategies-for-identifying-and-engaging-pharmaceutical-industry-s-rising-stars 2016-03-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-reveals-key-strategies-for-identifying-and-engaging-pharmaceutical-industry-s-rising-stars 2016-03-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-launches-prime-initiative-to-accelerate-access-to-breakthrough-medicines-in-europe 2016-03-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-launches-prime-initiative-to-accelerate-access-to-breakthrough-medicines-in-europe 2016-03-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-multi-centre-three-arm-randomised-clinical-trial-viper 2016-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multi-centre-three-arm-randomised-clinical-trial-viper 2016-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/revlimid-lenalidomide-now-fda-approved-as-first-line 2016-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revlimid-lenalidomide-now-fda-approved-as-first-line 2016-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-for-adaptimmune-s-ny-eso-t-cell-therapy-in-synovial-sarcoma 2016-02-09T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-for-adaptimmune-s-ny-eso-t-cell-therapy-in-synovial-sarcoma 2016-02-09T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/tetanus-shot-enhances-survival-in-brain-tumor-immunotherapy 2016-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tetanus-shot-enhances-survival-in-brain-tumor-immunotherapy 2016-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1b-trial-of-dostarlimab-combinations-shows-promise-in-advanced-solid-tumors 2016-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1b-trial-of-dostarlimab-combinations-shows-promise-in-advanced-solid-tumors 2016-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-evaluates-intra-arterial-tenecteplase-following-endovascular-therapy-for-acute-stroke 2016-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-evaluates-intra-arterial-tenecteplase-following-endovascular-therapy-for-acute-stroke 2016-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/three-new-therapies-approved-for-multiple-myeloma 2016-01-06T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-new-therapies-approved-for-multiple-myeloma 2016-01-06T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-reporting-of-adverse-events-in-oncology-phase-iii-trials 2016-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-reporting-of-adverse-events-in-oncology-phase-iii-trials 2016-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-record-45-new-drugs-in-2015-led-by-breakthrough-cancer-immunotherapy-opdivo 2015-12-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-record-45-new-drugs-in-2015-led-by-breakthrough-cancer-immunotherapy-opdivo 2015-12-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-and-boehringer-ingelheim-announce-eur11-4b-asset-swap-deal-to-reshape-consumer-health-market 2015-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-and-boehringer-ingelheim-announce-eur11-4b-asset-swap-deal-to-reshape-consumer-health-market 2015-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-cancer-drug-development-pipeline-shows-promise-across-multiple-therapeutic-areas 2015-12-11T13:07:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-cancer-drug-development-pipeline-shows-promise-across-multiple-therapeutic-areas 2015-12-11T13:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/palbociclib-a-new-option-for-front-line-treatment 2015-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palbociclib-a-new-option-for-front-line-treatment 2015-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-bwel-trial-a-study-on-weight-loss-and-breast-cancer-recurrence 2015-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-bwel-trial-a-study-on-weight-loss-and-breast-cancer-recurrence 2015-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-trofinetide-for-rett-syndrome-treatment 2015-10-12T20:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-trofinetide-for-rett-syndrome-treatment 2015-10-12T20:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/india-modernizes-clinical-trial-process-with-digital-system-and-mandatory-av-consent-recording 2015-10-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-modernizes-clinical-trial-process-with-digital-system-and-mandatory-av-consent-recording 2015-10-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/smoking-poses-heightened-health-risks-for-hiv-patients-studies-show 2015-09-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/smoking-poses-heightened-health-risks-for-hiv-patients-studies-show 2015-09-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/federal-register-volume-90-issue-4-tuesday-january-7-2025-govinfo 2015-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/federal-register-volume-90-issue-4-tuesday-january-7-2025-govinfo 2015-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fulvestrant-500-mg-versus-anastrozole-1-mg-for-the-first 2015-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fulvestrant-500-mg-versus-anastrozole-1-mg-for-the-first 2015-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nice-provisionally-approves-biomarin-s-vimizim-for-ultra-rare-morquio-disease-with-real-world-data-requirements 2015-09-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nice-provisionally-approves-biomarin-s-vimizim-for-ultra-rare-morquio-disease-with-real-world-data-requirements 2015-09-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-two-new-ustekinumab-biosimilars-bringing-total-us-biosimilar-count-to-65 2015-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-two-new-ustekinumab-biosimilars-bringing-total-us-biosimilar-count-to-65 2015-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ropeginterferon-alfa-2b-a-novel-ifna-2b-induces-high 2015-08-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ropeginterferon-alfa-2b-a-novel-ifna-2b-induces-high 2015-08-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-expands-immuno-oncology-portfolio-with-three-strategic-partnerships 2015-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-expands-immuno-oncology-portfolio-with-three-strategic-partnerships 2015-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/europe-emerges-as-leading-hub-for-precision-medicine-innovation-and-implementation 2015-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/europe-emerges-as-leading-hub-for-precision-medicine-innovation-and-implementation 2015-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/india-revamps-clinical-trial-regulations-to-align-with-global-standards 2015-08-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-revamps-clinical-trial-regulations-to-align-with-global-standards 2015-08-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/who-welcomes-european-regulators-historic-green-light-for-first-malaria-vaccine 2015-07-24T14:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-welcomes-european-regulators-historic-green-light-for-first-malaria-vaccine 2015-07-24T14:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/palbociclib-for-the-treatment-of-estrogen-receptor 2015-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palbociclib-for-the-treatment-of-estrogen-receptor 2015-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/modified-herpes-virus-shows-promise-in-phase-3-melanoma-trial-improving-survival-by-20-months 2015-05-27T08:47:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modified-herpes-virus-shows-promise-in-phase-3-melanoma-trial-improving-survival-by-20-months 2015-05-27T08:47:54+00:00 weekly 0.7 https://trial.medpath.com/news/pancreatic-cancer-action-network-and-perthera-launch-know-your-tumor-initiative-for-precision-treatment 2015-05-07T00:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pancreatic-cancer-action-network-and-perthera-launch-know-your-tumor-initiative-for-precision-treatment 2015-05-07T00:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/free-light-chains-in-patients-with-acute-coronary-syndromes 2015-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/free-light-chains-in-patients-with-acute-coronary-syndromes 2015-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-revolutionizes-clinical-trial-recruitment-through-digital-innovation-and-social-media 2015-03-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-revolutionizes-clinical-trial-recruitment-through-digital-innovation-and-social-media 2015-03-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/poly-adp-ribose-polymerase-inhibitors-recent-advances-and-future 2015-03-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poly-adp-ribose-polymerase-inhibitors-recent-advances-and-future 2015-03-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-acquires-pharmacyclics-for-21-billion-to-secure-imbruvica-cancer-drug-rights 2015-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-acquires-pharmacyclics-for-21-billion-to-secure-imbruvica-cancer-drug-rights 2015-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-pipeline-targets 2015-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-biosciences-pipeline-targets 2015-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-validate-the-severity-of-persistent-lyme-disease 2015-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-validate-the-severity-of-persistent-lyme-disease 2015-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-shows-positive-impact-on-hta-drug-approvals-analysis-reveals 2015-01-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-shows-positive-impact-on-hta-drug-approvals-analysis-reveals 2015-01-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/beyond-the-pill-pharmaceutical-industry-shifts-focus-to-holistic-patient-solutions 2015-01-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beyond-the-pill-pharmaceutical-industry-shifts-focus-to-holistic-patient-solutions 2015-01-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-the-35-billion-biosimilar-market-new-marketing-paradigms-for-success 2015-01-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navigating-the-35-billion-biosimilar-market-new-marketing-paradigms-for-success 2015-01-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-bladder-cancer-treatment-with-new-immunotherapy-drug 2014-11-27T02:25:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-bladder-cancer-treatment-with-new-immunotherapy-drug 2014-11-27T02:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/ucla-gene-therapy-achieves-100-cure-rate-for-bubble-baby-disease-in-clinical-trials 2014-11-18T13:38:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucla-gene-therapy-achieves-100-cure-rate-for-bubble-baby-disease-in-clinical-trials 2014-11-18T13:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-pre-transplantation-minimal-residual-disease-mrd-on-the 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-pre-transplantation-minimal-residual-disease-mrd-on-the 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/topotecan-a-new-active-drug-in-the-second-line-treatment 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/topotecan-a-new-active-drug-in-the-second-line-treatment 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-landiolol-hydrochloride-an-ultra-short-acting-beta 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-landiolol-hydrochloride-an-ultra-short-acting-beta 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/surpass-et-phase-iii-study-of-ropeginterferon-alfa-2b-versus 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/surpass-et-phase-iii-study-of-ropeginterferon-alfa-2b-versus 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prospective-open-label-single-arm-single-center-follow 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prospective-open-label-single-arm-single-center-follow 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abemaciclib-a-potent-cyclin-dependent-kinase-4-and-6-inhibitor-for 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abemaciclib-a-potent-cyclin-dependent-kinase-4-and-6-inhibitor-for 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelics-for-patients-with-cancer-a-comprehensive-pubmed 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelics-for-patients-with-cancer-a-comprehensive-pubmed 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/persistent-lyme-empiric-antibiotic-study-europe-please-design-of-a 2014-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/persistent-lyme-empiric-antibiotic-study-europe-please-design-of-a 2014-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-leap-012-study-shows-promising-results-for-intermediate-stage-hcc-treatment 2014-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-leap-012-study-shows-promising-results-for-intermediate-stage-hcc-treatment 2014-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/south-korea-emerges-as-premier-clinical-trial-hub-with-20-billion-pharmaceutical-market-potential 2014-09-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-korea-emerges-as-premier-clinical-trial-hub-with-20-billion-pharmaceutical-market-potential 2014-09-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-in-oncology-recent-clinical-trial-findings 2014-09-10T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthroughs-in-oncology-recent-clinical-trial-findings 2014-09-10T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-evaluation-of-high-flow-nasal-cannula-and-conventional-o2-therapy-in-pediatric-cardiac-surgical-patients 2014-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-evaluation-of-high-flow-nasal-cannula-and-conventional-o2-therapy-in-pediatric-cardiac-surgical-patients 2014-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alternatives-to-opioids-in-the-pharmacologic-management 2014-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alternatives-to-opioids-in-the-pharmacologic-management 2014-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evolving-landscape-of-oncology-clinical-trials-expert-insights-on-precision-medicine-and-patient-recruitment 2014-07-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolving-landscape-of-oncology-clinical-trials-expert-insights-on-precision-medicine-and-patient-recruitment 2014-07-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/time-and-motion-studies-emerge-as-critical-tool-for-healthcare-efficiency-assessment 2014-07-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/time-and-motion-studies-emerge-as-critical-tool-for-healthcare-efficiency-assessment 2014-07-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/wales-launches-ps100-million-life-sciences-hub-to-boost-innovation-and-investment 2014-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wales-launches-ps100-million-life-sciences-hub-to-boost-innovation-and-investment 2014-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-hpv-dna-test-as-primary-cervical-cancer-screening-alternative-to-pap-smear 2014-04-25T01:41:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-hpv-dna-test-as-primary-cervical-cancer-screening-alternative-to-pap-smear 2014-04-25T01:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/elevated-bone-turnover-markers-predict-poor-survival-in-castration-resistant-prostate-cancer 2014-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevated-bone-turnover-markers-predict-poor-survival-in-castration-resistant-prostate-cancer 2014-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-strategies-for-patient-recruitment-in-rare-disease-trials-lessons-from-the-alkaptonuria-experience 2014-02-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-strategies-for-patient-recruitment-in-rare-disease-trials-lessons-from-the-alkaptonuria-experience 2014-02-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-clinical-trial-design-bridging-the-gap-between-regulatory-approval-and-market-access 2014-01-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-clinical-trial-design-bridging-the-gap-between-regulatory-approval-and-market-access 2014-01-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oasis-diagnostics-receives-michael-j-fox-foundation-grant-for-saliva-based-parkinson-s-test 2014-01-10T04:38:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oasis-diagnostics-receives-michael-j-fox-foundation-grant-for-saliva-based-parkinson-s-test 2014-01-10T04:38:18+00:00 weekly 0.7 https://trial.medpath.com/news/poly-adp-ribose-polymerase-parp-inhibitors-for-the 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poly-adp-ribose-polymerase-parp-inhibitors-for-the 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-natural-killer-cell-cancer-immunotherapy 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-natural-killer-cell-cancer-immunotherapy 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/administration-of-the-etonogestrel-contraceptive-implant-on 2013-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/administration-of-the-etonogestrel-contraceptive-implant-on 2013-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rare-disease-research-faces-critical-funding-gap-despite-scientific-value 2013-10-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rare-disease-research-faces-critical-funding-gap-despite-scientific-value 2013-10-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-for-myelofibrosis-an-update-of-its-clinical-effects 2013-10-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruxolitinib-for-myelofibrosis-an-update-of-its-clinical-effects 2013-10-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-150-years-of-pharmaceutical-innovation-and-global-healthcare-leadership 2013-08-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-150-years-of-pharmaceutical-innovation-and-global-healthcare-leadership 2013-08-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-healthcare-reform-ambitious-1-trillion-investment-plan-reshapes-market-access-landscape 2013-07-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-s-healthcare-reform-ambitious-1-trillion-investment-plan-reshapes-market-access-landscape 2013-07-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-breakthroughs-in-hematologic-malignancies-expert-highlights-promising-treatments-and-research-directions 2013-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emerging-breakthroughs-in-hematologic-malignancies-expert-highlights-promising-treatments-and-research-directions 2013-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-s-strategic-approach-to-global-pharmacovigilance-balancing-innovation-with-patient-safety 2013-07-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-s-strategic-approach-to-global-pharmacovigilance-balancing-innovation-with-patient-safety 2013-07-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-complex-safety-evaluations-in-early-phase-cancer-drug-development 2013-07-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navigating-complex-safety-evaluations-in-early-phase-cancer-drug-development 2013-07-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/italian-pharmaceutical-market-faces-1-6b-decline-as-government-pushes-generic-drug-adoption 2013-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/italian-pharmaceutical-market-faces-1-6b-decline-as-government-pushes-generic-drug-adoption 2013-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-market-access-hurdles-loom-for-pd-1-pd-l1-immunotherapies-in-oncology 2013-06-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-market-access-hurdles-loom-for-pd-1-pd-l1-immunotherapies-in-oncology 2013-06-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rising-costs-and-success-rates-the-complex-economics-of-oncology-drug-development 2013-06-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-costs-and-success-rates-the-complex-economics-of-oncology-drug-development 2013-06-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-gives-update-on-the-clinical-development-of-its-lead-cancer 2013-05-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-gives-update-on-the-clinical-development-of-its-lead-cancer 2013-05-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-serono-and-quintiles-forge-groundbreaking-5-year-clinical-development-partnership 2013-05-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-serono-and-quintiles-forge-groundbreaking-5-year-clinical-development-partnership 2013-05-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-payers-show-flexibility-in-nebulizer-access-despite-limited-clinical-evidence-in-asthma-treatment 2013-04-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-payers-show-flexibility-in-nebulizer-access-despite-limited-clinical-evidence-in-asthma-treatment 2013-04-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/temozolomide-s-effectiveness-in-treating-high-grade-glioma 2013-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/temozolomide-s-effectiveness-in-treating-high-grade-glioma 2013-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-s-evolution-in-social-media-from-listening-to-collaboration-in-rare-disease-communities 2013-02-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-s-evolution-in-social-media-from-listening-to-collaboration-in-rare-disease-communities 2013-02-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/home-healthcare-services-emerge-as-strategic-priority-for-pharmaceutical-companies 2013-02-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/home-healthcare-services-emerge-as-strategic-priority-for-pharmaceutical-companies 2013-02-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-new-draft-guidance-for-early-stage-alzheimer-s-drug-development 2013-02-12T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-new-draft-guidance-for-early-stage-alzheimer-s-drug-development 2013-02-12T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-push-for-clinical-trial-transparency-gains-momentum-with-ema-and-alltrials-campaign 2013-01-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-push-for-clinical-trial-transparency-gains-momentum-with-ema-and-alltrials-campaign 2013-01-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-and-biological-e-form-joint-venture-to-develop-novel-six-in-one-pediatric-vaccine 2013-01-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-and-biological-e-form-joint-venture-to-develop-novel-six-in-one-pediatric-vaccine 2013-01-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cook-medical-s-zilver-ptx-becomes-first-fda-approved-drug-eluting-peripheral-stent-in-u-s-market 2013-01-16T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cook-medical-s-zilver-ptx-becomes-first-fda-approved-drug-eluting-peripheral-stent-in-u-s-market 2013-01-16T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-extended-release-diphenidol-formulation-reduces-dosing-frequency-while-maintaining-therapeutic-plasma-levels 2013-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-extended-release-diphenidol-formulation-reduces-dosing-frequency-while-maintaining-therapeutic-plasma-levels 2013-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-spin-outs-emerge-as-critical-bridge-between-academia-and-pharma-r-d 2012-12-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-spin-outs-emerge-as-critical-bridge-between-academia-and-pharma-r-d 2012-12-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-approval-of-selincro-for-alcohol-dependency-treatment 2012-12-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-recommends-approval-of-selincro-for-alcohol-dependency-treatment 2012-12-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emotional-marketing-in-pharma-evidence-shows-power-of-combining-rational-and-emotional-appeals 2012-11-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emotional-marketing-in-pharma-evidence-shows-power-of-combining-rational-and-emotional-appeals 2012-11-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-journey-from-vitamin-production-pioneer-to-personalized-medicine-leader 2012-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-journey-from-vitamin-production-pioneer-to-personalized-medicine-leader 2012-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prucalopride-in-the-treatment-of-chronic-constipation 2012-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prucalopride-in-the-treatment-of-chronic-constipation 2012-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/suppl-1-a-reappraisal-of-the-u-s-clinical-trials-of-post-treatment 2012-10-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suppl-1-a-reappraisal-of-the-u-s-clinical-trials-of-post-treatment 2012-10-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-and-bristol-myers-squibb-restructure-alliance-following-patent-expirations 2012-10-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-and-bristol-myers-squibb-restructure-alliance-following-patent-expirations 2012-10-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-confirms-efficacy-of-ulipristal-acetate-as-emergency-contraception 2012-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-confirms-efficacy-of-ulipristal-acetate-as-emergency-contraception 2012-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-giants-embrace-open-science-pfizer-merck-lead-industry-transformation 2012-08-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-giants-embrace-open-science-pfizer-merck-lead-industry-transformation 2012-08-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nih-expert-outlines-critical-challenges-and-solutions-in-rare-disease-clinical-trials 2012-08-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-expert-outlines-critical-challenges-and-solutions-in-rare-disease-clinical-trials 2012-08-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-clinical-trial-outsourcing-could-save-pharma-industry-billions-experts-say 2012-07-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-clinical-trial-outsourcing-could-save-pharma-industry-billions-experts-say 2012-07-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-clinical-trials-navigating-challenges-and-opportunities-in-modern-drug-development 2012-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-clinical-trials-navigating-challenges-and-opportunities-in-modern-drug-development 2012-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-biosimilars-market-set-to-reach-2-3-billion-by-2015-as-industry-faces-development-challenges 2012-04-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biosimilars-market-set-to-reach-2-3-billion-by-2015-as-industry-faces-development-challenges 2012-04-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-treatment-doubles-skin-cancer-drug-s-effectiveness 2012-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-treatment-doubles-skin-cancer-drug-s-effectiveness 2012-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-biosimilars-market-set-to-reach-3-99-billion-by-2017-as-industry-embraces-complex-biologics 2012-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biosimilars-market-set-to-reach-3-99-billion-by-2017-as-industry-embraces-complex-biologics 2012-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/india-s-complex-regulatory-landscape-poses-major-hurdles-for-pharmaceutical-approvals 2012-02-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-s-complex-regulatory-landscape-poses-major-hurdles-for-pharmaceutical-approvals 2012-02-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glucose-dependent-insulinotropic-polypeptide-reduces 2012-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glucose-dependent-insulinotropic-polypeptide-reduces 2012-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/obinutuzumab-shows-promise-in-treating-proliferative-lupus-nephritis-in-phase-2-trial 2012-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obinutuzumab-shows-promise-in-treating-proliferative-lupus-nephritis-in-phase-2-trial 2012-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/barriers-to-personalized-medicine-payer-reimbursement-challenges-slow-diagnostic-test-adoption 2011-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/barriers-to-personalized-medicine-payer-reimbursement-challenges-slow-diagnostic-test-adoption 2011-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-car-modified-t-cells-for-leukemia-treatment 2011-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-car-modified-t-cells-for-leukemia-treatment 2011-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xarelto-okayed-by-fda-for-treating-atrial-fibrillation-cbs-news 2011-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xarelto-okayed-by-fda-for-treating-atrial-fibrillation-cbs-news 2011-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lifestyle-and-metformin-interventions-show-significant-benefits-in-diabetes-prevention 2011-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifestyle-and-metformin-interventions-show-significant-benefits-in-diabetes-prevention 2011-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/four-key-drivers-reshaping-successful-oncology-drug-launches-in-modern-market 2011-08-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/four-key-drivers-reshaping-successful-oncology-drug-launches-in-modern-market 2011-08-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-lung-cancer-screening-ct-scans-reduce-mortality 2011-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-lung-cancer-screening-ct-scans-reduce-mortality 2011-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lialda-for-maintenance-of-remission-in-ulcerative-colitis-patients 2011-07-18T15:41:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lialda-for-maintenance-of-remission-in-ulcerative-colitis-patients 2011-07-18T15:41:37+00:00 weekly 0.7 https://trial.medpath.com/news/cetuximab-enhances-treatment-efficacy-for-metastatic-colorectal-cancer-with-kras-wild-type 2011-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cetuximab-enhances-treatment-efficacy-for-metastatic-colorectal-cancer-with-kras-wild-type 2011-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/metallic-copper-as-an-antimicrobial-surface-a-comprehensive-review 2010-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metallic-copper-as-an-antimicrobial-surface-a-comprehensive-review 2010-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-pharmaceutical-r-d-outsourcing-trends-industry-shifts-toward-strategic-partnerships-and-offshore-operations 2010-09-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-pharmaceutical-r-d-outsourcing-trends-industry-shifts-toward-strategic-partnerships-and-offshore-operations 2010-09-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urovant-sciences-announces-u-s-fda-approval-of-gemtesa 2010-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urovant-sciences-announces-u-s-fda-approval-of-gemtesa 2010-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-economic-pressures-force-pharmaceutical-industry-to-confront-radical-transformation 2010-05-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-economic-pressures-force-pharmaceutical-industry-to-confront-radical-transformation 2010-05-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kras-mutation-in-stage-iii-colon-cancer-and-clinical-outcome-following-intergroup-trial-calgb-89803 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kras-mutation-in-stage-iii-colon-cancer-and-clinical-outcome-following-intergroup-trial-calgb-89803 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-access-to-investigational-drugs-for-treatment-use 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-access-to-investigational-drugs-for-treatment-use 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-sanofi-s-multaq-for-atrial-fibrillation-patients-marking-first-new-treatment-in-two-decades 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-sanofi-s-multaq-for-atrial-fibrillation-patients-marking-first-new-treatment-in-two-decades 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nz-scientist-s-gene-research-offers-hope-against-obesity-epidemic 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nz-scientist-s-gene-research-offers-hope-against-obesity-epidemic 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-guidance-for-cardiovascular-risk-assessment-of-novel-antidiabetic-agents 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-guidance-for-cardiovascular-risk-assessment-of-novel-antidiabetic-agents 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/wuxi-pharmatech-strengthens-board-with-strategic-appointments-of-industry-veterans 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wuxi-pharmatech-strengthens-board-with-strategic-appointments-of-industry-veterans 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-treatment-successes-identified-in-phase-3-trials 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-cancer-treatment-successes-identified-in-phase-3-trials 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ku-team-announces-breakthrough-in-leishmaniasis-treatment 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ku-team-announces-breakthrough-in-leishmaniasis-treatment 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-on-adherence-to-glaucoma-medication-regimens 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-on-adherence-to-glaucoma-medication-regimens 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-contraception-with-mifepristone 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-contraception-with-mifepristone 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/progress-and-challenges-in-developing-blood-stage-malaria-vaccines 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/progress-and-challenges-in-developing-blood-stage-malaria-vaccines 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/generalizability-in-two-clinical-trials-of-lyme-disease-pmc 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/generalizability-in-two-clinical-trials-of-lyme-disease-pmc 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-implantable-artificial-heart-gets-fdas-approval 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-implantable-artificial-heart-gets-fdas-approval 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-insights-into-bladder-cancer-screening-and-awareness-campaign-launch 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-insights-into-bladder-cancer-screening-and-awareness-campaign-launch 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/honorhealth-s-cancer-research-program-a-leader-in-clinical-trials-and-treatment-innovation 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/honorhealth-s-cancer-research-program-a-leader-in-clinical-trials-and-treatment-innovation 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-and-treatment-of-post-lyme-disease-stop-ld 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-and-treatment-of-post-lyme-disease-stop-ld 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-expanded-use-of-med-el-cochlear-implant-system 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-expanded-use-of-med-el-cochlear-implant-system 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/home-based-exercise-program-significantly-reduces-knee-pain-study-finds 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/home-based-exercise-program-significantly-reduces-knee-pain-study-finds 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-cphpc-drug-shows-promise-in-breaking-down-alzheimer-s-amyloid-clumps 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-cphpc-drug-shows-promise-in-breaking-down-alzheimer-s-amyloid-clumps 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/culturally-tailored-interventions-boost-cervical-cancer-screening-among-chinese-women-in-north-america 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/culturally-tailored-interventions-boost-cervical-cancer-screening-among-chinese-women-in-north-america 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-treatment-beating-ovarian-cancer 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-treatment-beating-ovarian-cancer 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-antithymocyte-globulin-therapy-enhances-survival-in-steroid-resistant-acute-gvhd-patients 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-antithymocyte-globulin-therapy-enhances-survival-in-steroid-resistant-acute-gvhd-patients 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/asco-2024-lenvatinib-plus-pembrolizumab-shows-superiority-over-sunitinib-in-advanced-renal-cell-carcinoma 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asco-2024-lenvatinib-plus-pembrolizumab-shows-superiority-over-sunitinib-in-advanced-renal-cell-carcinoma 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pembrolizumab-for-advanced-esophageal-squamous-cell-cancer-with-pd-l1-expression 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pembrolizumab-for-advanced-esophageal-squamous-cell-cancer-with-pd-l1-expression 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regional-chemotherapy-for-liver-metastases-of-colorectal-cancer-shows-varied-perfusion-patterns 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regional-chemotherapy-for-liver-metastases-of-colorectal-cancer-shows-varied-perfusion-patterns 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regional-chemotherapy-shows-promise-in-treating-colorectal-cancer-metastatic-to-the-liver 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regional-chemotherapy-shows-promise-in-treating-colorectal-cancer-metastatic-to-the-liver 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d3bio-s-novel-kras-g12c-inhibitor-shows-promising-results-in-phase-1-cancer-trial 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/d3bio-s-novel-kras-g12c-inhibitor-shows-promising-results-in-phase-1-cancer-trial 2010-01-01T00:00:00+00:00 weekly 0.7